中文名 | 宝藿苷I |
英文名 | baohuoside I |
别名 | 宝藿苷Ⅰ 宝藿苷I 宝藿苷I(标准品) 宝藿苷I,淫羊藿次苷Ⅱ 宝藿苷I, 来源于淫羊藿 BAOHUOSIDE I 宝藿苷I BAOHUOSIDE I 宝藿苷I 标准品 宝霍苷I((淫羊藿次苷II,脱水淫羊藿苷) |
英文别名 | Icariin II Icarisid II Baohuoside-1 BAOHUOSIDE I baohuoside I Baohuoside I ICARISIDE II ANHYDROICARITIN Baohuoside I(Icariside II) 3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside 5,7-Dihydroxy-4'-methoxy-8-prenyl-3-(α-L-rhamnopyranosyloxy)flavone 3-(α-L-Rhamnopyranosyloxy)-4'-methoxy-5,7-dihydroxy-8-prenylflavone 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-chromen-3-yl 6-deoxy-alpha-L-mannopyranoside 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)- |
CAS | 113558-15-9 |
化学式 | C27 H30 O10 |
分子量 | 514.52 |
InChI | InChI=1/C27H30O10/c1-12(2)5-10-16-17(28)11-18(29)19-21(31)26(37-27-23(33)22(32)20(30)13(3)35-27)24(36-25(16)19)14-6-8-15(34-4)9-7-14/h5-9,11,13,20,22-23,27-30,32-33H,10H2,1-4H3/t13-,20-,22+,23+,27-/m0/s1 |
密度 | 1.46 |
熔点 | 202-203 °C |
沸点 | 759.4±60.0 °C(Predicted) |
比旋光度 | (c, 0.09 in MeOH)-121 |
闪点 | 253.8°C |
蒸汽压 | 3.07E-24mmHg at 25°C |
溶解度 | DMSO、甲醇 |
折射率 | 1.666 |
酸度系数 | 6.29±0.40(Predicted) |
存储条件 | Inert atmosphere,Room Temperature |
外观 | 固体 |
颜色 | Light Yellow |
物化性质 | 黄色针状结晶,溶于甲醇,来源于淫羊藿全草。 |
MDL号 | MFCD15071140 |
体外研究 | Baohuoside I is an inhibitor of CXCR4, and downregulates CXCR4 expression at 12-25 μM. Baohuoside I (0-25 μM) suppresses NF-κB activation in a dose-dependent manner, suppresses CXCL12 induced the invasion of cervical cancer cells. Baohuoside I also inhibits invasion of breast cancer cells. Baohuoside I inhibits A549 cell viability, with IC 50 s of 25.1 μM at 24 h, 11.5 μM and 9.6 μM at 48 h and 72 h, respectively. Baohuoside I ((25 μM) suppresses the caspase cascade in A549 cells, elevates ROS levels and activates JNK and p38 MAPK signaling cascade. Baohuoside I (3.125, 6.25, 12.5, 25.0 and 50.0 µg/mL) significantly and dose-dependently blocks the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC 50 of 4.8 µg/mL at 48 h. |
体内研究 | Baohuoside I (25 mg/kg) decreases β-catenin protein levels, cyclin D1 and survivin expression in nude mice. |
海关编号 | 29329990 |
下游产品 | 去水淫羊藿黄素 |
参考资料 展开查看 | 1. 杨轶舜 张彤 丁越 等. 3种淫羊藿苷次生产物的制备及HPLC测定[J]. 中成药 2020 042(003):779-782. 2. 李瑞云 刘聪燕 许婷 等. 交联纳米SiO_2固定化蜗牛酶的制备表征及转化淫羊藿苷研究[J]. 中草药 2019 v.50;No.655(20):57-63. 3. 高霞, 陈彦, 王莹,等. 淫羊藿苷仿生酶解过程的多因素考察[J]. 药学学报, 2013(11):1716-1721. 4. 刘玉萍, 丁学芳, 黄萌萌,等. 淫羊藿苷在不同骨质疏松大鼠模型中肠道吸收代谢研究[J]. 中国中药杂志, 2016(13):2532-2537. 5. 顾慧敏, 孙娥, 李杰,等. 炮制辅料羊脂油对宝藿苷Ⅰ-胆酸盐自组装胶束形成与吸收的影响[J]. 中国中药杂志, 2019, v.44(23):133-140. 6. 杨茹 刘聪燕 许婷 等. 5种大孔吸附树脂对淫羊藿总黄酮的吸附特性考察[J]. 中国实验方剂学杂志 2020 v.26(06):121-128. 7. 王莹 高霞 陈彦 等. 卡波姆对淫羊藿总黄酮酶解效果的影响[J]. 中国实验方剂学杂志 2014 20(009):1-5. 8. 刘聪燕 高霞 陈彦 等. 仿生酶解肠溶胶囊提高淫羊藿总黄酮口服生物利用度的可行性研究[J]. 中国医药工业杂志 2016(9期):1158-1164. 9. 张燕. 大孔吸附树脂分离纯化淫羊藿EF5黄酮[J]. 北方药学, 2015, 000(011):11-13. 10. 刘聪燕, 高霞, 黄萌萌,等. 淫羊藿总黄酮仿生酶解肠溶胶囊的制备及评价[J]. 中草药, 2016(20). 11. 刘聪燕, 高霞, 陈彦,等. 淫羊藿总黄酮在骨质疏松大鼠体内的药动学行为[J]. 中成药, 2017, 39(008):1595-1600. 12. 高霞, 刘璇, 陈彦,等. 淫羊藿总黄酮的生物转化过程分析[J]. 中国中药杂志, 2013, 38(23):4079. 13. 高霞, 陈彦, 王莹,等. 糊精湿法制粒对淫羊藿总黄酮酶解的影响[J]. 中成药, 2014, 36(007):1392-1397. 14. 彭静, 马益华, 陈彦,等. 固定化蜗牛酶同时生物转化淫羊藿中4种黄酮苷[J]. 中成药, 2016, 38(9):1984-1990. 15. 刘聪燕,李瑞云,马程遥,刘玉萍,瞿鼎,李晓琦,陈彦.壳聚糖交联介孔二氧化硅固定化β-葡萄糖苷酶生物转化淫羊藿苷研究[J].中草药,2021,52(03):685-691. 16. 许婷,黄萌萌,李瑞云,杨茹,刘丽芳,陈彦.多基原淫羊藿不同部位质量评价研究[J].中草药,2020,51(01):190-196. 17. Yang, Jing, et al. "Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells." European journal of pharmacology 846 (2019): 12-22.https://doi.org/10.1016/j.ejphar.2018.12.026 18. Liu, Congyan, et al. "Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats." Biomedicine & Pharmacotherapy 94 (2017): 1048-1056.https://doi.org/10.1016/j.biopha.2017.07.163 19. [IF=6.529] Congyan Liu et al."Icariin combined with snailase shows improved intestinal hydrolysis and absorption in osteoporosis rats."Biomed Pharmacother. 2017 Oct;94:1048 20. [IF=3.263] Jing Yang et al."Icariside II induces cell cycle arrest and differentiation via TLR8/MyD88/p38 pathway in acute myeloid leukemia cells."Eur J Pharmacol. 2019 Mar;846:12 21. [IF=4.411] Zhenxian Qin et al."A Widely Metabolomic Analysis Revealed Metabolic Alterations of Epimedium Pubescens Leaves at Different Growth Stages."Molecules. 2020 Jan;25(1):137 22. [IF=4.36] Kun Shi et al."Epimedii Folium and Curculiginis Rhizoma ameliorate lipopolysaccharides-induced cognitive impairment by regulating the TREM2 signaling pathway."J Ethnopharmacol. 2022 Feb;284:114766 23. [IF=3.757] Congyan Liu et al."Enhanced hydrolysis and antitumor efficacy of Epimedium flavonoids mediated by immobilized snailase on silica."Process Biochem. 2019 Nov;86:80 24. [IF=3.645] Hongmin Zhang et al."Simultaneous determination of five isoflavones in rat plasma by LC-MS/MS: Comparative pharmacokinetic characteristics of Puerariae lobatae radix in normal and type 2 diabetic rats."J Sep Sci. 2019 Aug;42(16):2592-2601 25. [IF=2.886] Fubiao Ni et al."Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling."Cancer Manag Res. 2019; 11: 10609–10621 26. [IF=2.886] Yangyang Guo et al."Baohuoside I via mTOR Apoptotic Signaling to Inhibit Glioma Cell Growth."Cancer Manag Res. 2020; 12: 11435–11444 27. [IF=1.902] Ting Zhang et al."The influence of essential oils from ZhaLi NuSi Prescription on the pharmacokinetics of its non-volatile components in normal rats."Biomedical Chromatography. 2021 Oct 21 |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!